Predictive value of neutrophil-lymphocyte ratio for prognosis in patients with advanced hepatocellular carcinoma treated with programmed cell death 1 inhibitors

Table 3 Multivariate logistic regression analysis of factors influencing poor prognosis

Variable	Coefficient	SE	Wald stat	P value	OR	OR CI lower	OR CI upper
BCLC stage (C vs B)	0.849	0.429	1.978	0.048	2.336	1.008	5.413
Maximum tumor diameter (cm)	0.286	0.098	2.920	0.004	1.331	1.098	1.612
Macrovascular invasion (yes vs no)	0.452	0.391	1.156	0.248	1.572	0.730	3.382
Extrahepatic spread (yes vs no)	0.609	0.424	1.438	0.150	1.839	0.802	4.218
AFP (ng/mL)	0.006	0.001	4.668	< 0.001	1.006	1.004	1.009
NLR	1.474	0.273	5.402	< 0.001	4.365	2.557	7.451
AST (U/L)	0.038	0.015	2.523	0.012	1.039	1.008	1.070
Total bilirubin (μmol/L)	0.112	0.044	2.560	0.010	1.119	1.027	1.219
Albumin (g/L)	-0.127	0.050	-2.524	0.012	0.880	0.798	0.972
International normalized ratio	0.438	0.723	0.605	0.545	1.549	0.375	6.390

BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha fetoprotein; NLR: Neutrophil-to-lymphocyte ratio; AST: Aspartate aminotransferase; CI: Confidence interval; OR: Odds ratio.